Localised prostate cancer just changed. Again.
ESMO 2026 brings clarity on who to observe, who to escalate, and which trials actually matter 👇
🧠 Diagnosis
MRI before biopsy is standard
High-resolution US is a valid alternative (RCT n=678)
🧭 Low risk
Active surveillance is safe
ProtecT 15-yr data shows similar survival vs RP/RT
☢️ Radiotherapy
Shorter is better
CHHiP ➜ moderate hypofractionation
HYPO-RT-PC ➜ ultra-hypofractionation
PACE-B ➜ SBRT works in selected IR disease
📈 High risk
RT + long-term ADT saves lives
SPCG-7 | NCIC/MRC
Dose escalation improves OS (GETUG-AFU 18)
🚨 Very high-risk / cN1
RT + ADT + abiraterone is the new benchmark
STAMPEDE delivers MFS + OS benefit
🔁 Biochemical recurrence
Avoid routine adjuvant RT
Early salvage RT preferred
RADICALS-RT | RAVES | GETUG-AFU 17
High-risk BCR? Intensify
EMBARK supports enzalutamide + ADT
🧠 Bottom line
Risk-adapted care > overtreatment
Imaging-driven decisions
Escalate only when trials prove benefit
📖 Full paper in comment ⬇️
#OncoTwitter #MedTwitter #ProstateCancer #GUOncology
@OncoAlert@myesmo@esmo_open@asco@OncBrothers
Wonderful conference in Penang, Malaysia.,thanks to the Malaysian Urological Association for the opportunity to perform Live demonstration of Mini PCNL. Very well attended conf.great, scientific program and appreciate the royal Hospitality.
Another valuable publication from "International Alliance of Urolithiasis (IAU) "focusing on the routine application of RIRS in clinical practice.Thanks for the generous efforts given by the renown experts in this field of endourology. An excellent guide for the young urologists.
Great session today afternoon with insightful talks and learning to troubleshoot PCNL/ECIRS. With @kmoretry@takatakaJinoue@henrygit
Learn from others' experiences if possible, and every time you teach you learn something new yourself.
#pcnl#ecirs#ETS
Only two weeks are left. Please join the Endoluminal Technology Symposium, 1st installment in Japan! Takaaki Inoue
Jan 29, 2022 (Sat) 2pm (GMT+9)
https://t.co/eOpW7R8wJ0
ETS in Asia starts in 2022 with 4 installments. Dr.Takaaki Inoue @takatakaJinoue will host the 1st installment seminar on Jan 29, 2022. Register:https://t.co/eOpW7RqFX8
The second crossfire in #MUC2021 featuring two esteemed speakers from the International Alliance of Urolithiasis, Prof Zeng Guohua and Prof Petrisor Geavlete.
A very nice collaboration of International Alliance of Urolithiasis(IAU)with EULIS..Well provided update on the actual treatment of renal stones with RIRS based on consensus among experts from all around the world. Thanks to all valuable "brothers and sisters in stone" involved..
The majority of polled Endourologists would choose SWL over ureteroscopy for their own 8mm upper ureteric stone.
Sorry @OTRAXER and @OJWiseman 🤷♂️
#UroSoMe